451 related articles for article (PubMed ID: 30159035)
1. Cholestatic liver diseases: new targets, new therapies.
Santiago P; Scheinberg AR; Levy C
Therap Adv Gastroenterol; 2018; 11():1756284818787400. PubMed ID: 30159035
[TBL] [Abstract][Full Text] [Related]
2. Chronic cholestatic diseases.
Poupon R; Chazouillères O; Poupon RE
J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
[TBL] [Abstract][Full Text] [Related]
3. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
4. The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities.
Mazzetti M; Marconi G; Mancinelli M; Benedetti A; Marzioni M; Maroni L
J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33919600
[TBL] [Abstract][Full Text] [Related]
5. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
6. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
8. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis.
Sakisaka S; Kawaguchi T; Taniguchi E; Hanada S; Sasatomi K; Koga H; Harada M; Kimura R; Sata M; Sawada N; Mori M; Todo S; Kurohiji T
Hepatology; 2001 Jun; 33(6):1460-8. PubMed ID: 11391535
[TBL] [Abstract][Full Text] [Related]
9. Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis.
Braadland PR; Schneider KM; Bergquist A; Molinaro A; Lövgren-Sandblom A; Henricsson M; Karlsen TH; Vesterhus M; Trautwein C; Hov JR; Marschall HU
JHEP Rep; 2022 Nov; 4(11):100561. PubMed ID: 36176935
[TBL] [Abstract][Full Text] [Related]
10. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
12. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
13. An update on the management of cholestatic liver diseases.
Appanna G; Kallis Y
Clin Med (Lond); 2020 Sep; 20(5):513-516. PubMed ID: 32934048
[TBL] [Abstract][Full Text] [Related]
14. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Rust C; Beuers U
Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
[TBL] [Abstract][Full Text] [Related]
15. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
16. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
17. Current pharmacotherapy for cholestatic liver disease.
Carey EJ; Lindor KD
Expert Opin Pharmacother; 2012 Dec; 13(17):2473-84. PubMed ID: 23094715
[TBL] [Abstract][Full Text] [Related]
18. Keratin 7 expression in hepatic cholestatic diseases.
Sakellariou S; Michaelides C; Voulgaris T; Vlachogiannakos J; Manesis E; Tiniakos DG; Delladetsima I
Virchows Arch; 2021 Oct; 479(4):815-824. PubMed ID: 34312700
[TBL] [Abstract][Full Text] [Related]
19. Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.
Sclair SN; Little E; Levy C
Clin Transl Gastroenterol; 2015 Aug; 6(8):e109. PubMed ID: 26312413
[TBL] [Abstract][Full Text] [Related]
20. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists.
Abenavoli L; Procopio AC; Fagoonee S; Pellicano R; Carbone M; Luzza F; Invernizzi P
Diseases; 2020 Jun; 8(2):. PubMed ID: 32532037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
